Rapport Therapeutics Stock (NASDAQ: RAPP)

Rapport Therapeutics

Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.

Stock market analysts

News

Initiation

Markets

Analyst Ratings

Trading Ideas

COFS

NEON

RAPP

SELF

This Rapport Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Movers

Intraday Update

AIRJ

AISP

ARRY

BNED

BWAQ

CAMP

CLSK

CRBP

CTGO

CURI

CVGW

GWAV

HOTH

KITT

KXIN

LXEH

MIND

MITQ

PIXY

PROK

RBOT

SHLS

SIFY

TPET

UBXG

YEXT

Why Contango Ore Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

Rapport Therapeutics, Inc. - Common Stock

Rapport Therapeutics Inc

Press Releases

Rapport Therapeutics to Present at 22nd Annual Morgan Stanley Global Healthcare Conference and TD Cowen's 4th Annual Novel Mechanisms in Neuropsychiatry Summit

Rapport Therapeutics to Present at Upcoming Epilepsy Medical Conferences

Rapport Therapeutics to Present at Stifel Healthcare Conference and Jefferies London Healthcare Conference in November

Earnings

Rapport Therapeutics Reports Third Quarter Financials and Provides Business Update

Health Care

Rapport Therapeutics to Present Data at American Epilepsy Society Annual Meeting

Rapport Therapeutics Presents Data Demonstrating Consistent Association Between Decreases in RNS Measured Long Episodes and Meaningful Reductions in Clinical Seizures

Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders

CORRECTION -- Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders

Rapport Therapeutics to Participate in Upcoming Investor Conferences

Management

Rapport Therapeutics Announces Appointment of Dr. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine Development

Aardvark Therapeutics, Inc. - Common Stock

Aardvark Therapeutics

Aclaris Therapeutics, Inc. - Common Stock

Aclaris Therapeutics

Alumis

Amylyx Pharmaceuticals, Inc. - Common Stock

Amylyx Pharma

Aquestive Therapeutics, Inc. - Common Stock

Aquestive Therapeutics

Atea Pharmaceuticals, Inc. - common stock

Atea Pharmaceuticals

Esperion Therapeutics, Inc. - Common Stock

Esperion Therapeutics

Eton Pharmaceuticals, Inc. - Common Stock

Eton Pharmaceuticals

EyePoint Pharmaceuticals, Inc. - Common Stock

EyePoint Pharmaceuticals

Fulcrum Therapeutics, Inc. - Common Stock

Fulcrum Therapeutics

GH Research

Maze Therapeutics

MBX Biosciences

Neumora Therapeutics, Inc. - Common Stock

Neumora Therapeutics

Omeros

Phathom Pharmaceuticals, Inc. - Common Stock

Phathom Pharmaceuticals

Septerna

SIGA Technologies

SNDL

Theravance Biopharma, Inc. - Ordinary Shares

Theravance Biopharma

Terns Pharmaceuticals, Inc. - Common Stock

Terns Pharma

Trevi Therapeutics

Xeris Biopharma Holdings, Inc. - Common Stock

Xeris Biopharma Holdings

Zevra Therapeutics

Zhengye Biotechnology Holding Limited - Ordinary Shares

Zhengye Biotechnology

Jones Trading

Stifel

Jefferies

Comments

Rapport Therapeutics

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga